<DOC>
	<DOCNO>NCT00649298</DOCNO>
	<brief_summary>This study assess clinical outcome extend weekly hour haemodialysis ( &gt; = 24 hour per week ) compare standard hour haemodialysis ( &lt; =18 hours/week ) people ESKD .</brief_summary>
	<brief_title>A Clinical Trial IntensiVE Dialysis</brief_title>
	<detailed_description>A rapidly increasing volume observational data suggest substantial benefit may associate increased duration dialysis . As well improve quality life , improve function beneficial change variety laboratory parameter , suggest extended dialysis session might reduce mortality major morbidity . Uncontrolled data centre provide extended dialysis show dramatically low mortality rate compare observed centre provide standard duration dialysis . Recent analysis extend dialysis conclude saving achieve drug hospitalization cost may lead overall reduction cost compare traditional form dialysis . In trial , propose examine effect extend dialysis ( 24 hour weekly ) compare standard dialysis ( 18 hour less weekly ) patient ESKD . The propose study multi-centre , open label , randomise , control trial . The study begin pilot phase convert current main study receipt peer-reviewed funding full study .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Incident prevalent patient require maintenance haemodialysis therapy ESKD 2 . Aged 18 year old 3 . Undergoing dialysis 18 hour per week le 4 . Suitable either extended standard dialysis view treat physician 5 . Agreeable randomisation 1 . Life expectancy le 6 month 2 . Definite plan undergo renal transplantation within 12 month entry study 3 . Inability complete quality life questionnaire 4 . Concomitant major illness would limit assessment followup 5 . High chance patient adhere study treatment follow view treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Controlled Clinical Trial</keyword>
	<keyword>Clinical Trial , Phase IV</keyword>
	<keyword>Multicenter Study</keyword>
	<keyword>End Stage Kidney Disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Renal Replacement Therapy</keyword>
	<keyword>Nocturnal Dialysis</keyword>
	<keyword>Extended dialysis</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Quality Adjusted Life Year</keyword>
	<keyword>Hypertrophy , Left Ventricular</keyword>
	<keyword>Blood Pressure</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Anemia</keyword>
	<keyword>Hematinics</keyword>
	<keyword>Erythropoiesis Stimulating Agents</keyword>
	<keyword>Cost-utility Analysis</keyword>
	<keyword>Economic Evaluation</keyword>
	<keyword>Health Care Utilisation</keyword>
	<keyword>Health Care Costs</keyword>
	<keyword>Health Expenditures</keyword>
	<keyword>Hospitalization</keyword>
	<keyword>Cost Analysis</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Stroke</keyword>
	<keyword>Cerebrovascular Disorders</keyword>
	<keyword>Mortality</keyword>
	<keyword>Arteriovenous Fistula</keyword>
	<keyword>Arteriovenous Shunt , Surgical</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Infection</keyword>
</DOC>